Chemotherapy in gastric cancer

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1213-1219

  Wöll, Ewald ^a,f   Devries, Alexander ^b   Eisterer, Wolfgang ^c   Hejna, Michael ^d   Keil, Felix ^d   Stein, Hubert ^e   Zacherl, Johannes ^d   Greil, Richard ^e  

^a Saint Vincent Hospital Zams   (Austria)

^b Landeskrankenhaus Feldkirch   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d MU Vienna ^*  (Austria)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f St Vinzenz Krankenhaus Betriebs GmbH   (Austria)

Author keywords

Chemotherapy; Gastric cancer; Review

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; TEGAFUR; URACIL;

ADJUVANT THERAPY; ALOPECIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DIARRHEA; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; STOMACH CANCER; TREATMENT DURATION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PALLIATIVE CARE; STOMACH NEOPLASMS;

EID: 42949177029     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Wagner AD et al: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 1, 2007 (ursprünglich publiziert in 2005;2:CD004064. doi:10.1002/14651858:CD004064.pub2.)
2. Glimelius B et al: Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8(2): 1-6,1997.
3. Van Cutsem E et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24(31): 4991-4997, 2006.
4. Webb A et al: Randomised trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15(1): 261-267, 1997.
5. Sumpter K et al: Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 92(11): 1976-1983, 2005.
6. Cunningham D et al: Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial (abstract). J Clin Oncol 24 (18S;Suppl.v.20. Juni):LBA4017 (Abstract online), 2006.
7. Cullinan SA et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253(14): 2061-2067, 1985.
8. Wils JA et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9(5): 827-831, 1991.
9. Kelsen D et al: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10(4): 541-548, 1992.
10. Vanhoefer U et al: Final results of a randomised phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18(14): 2648-2657, 2000.
11. Ross P et al: Prospective randomised trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20(8): 1996-2004, 2002.
12. Giordano KF et al: Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17(4): 652-656, 2006.
13. Kim JG et al: Phase II Study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 68(2-3): 190-195, 2005.
14. Chun JH et al: Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28(2): 188-194, 2005.
15. Park YH et al: A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 90(7): 1329-1333, 2004.
16. Ajani JA et al: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94(3): 641-646, 2002.
17. Bouche O et al: Randomised multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol 22(21): 4319-4328, 2004.
18. Wöll E et al: Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. Final results of a multicenter phase II trial (abstract). J Clin Oncol 24(18S;Suppl.v.20. Juni): 4070 (Abstract online: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/? vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD& vmview= abst_detail_view&confID=40&abstractID=31864, Stand: 4. April 2007), 2006.
19. Al-Batran S et al: A randomised phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) (abstract). J Clin Oncol 24(18S;Suppl.v.20. Juni):LBA4016 (Abstract online: http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 40&abstractID=33352, Stand: 4. April 2007), 2006.
20. Sadighi S et al: Quality of life in patients with advanced gastric cancer: a randomised trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 6: 274, 2006.
21. Shah MA et al: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24(33): 5201-5206, 2006.
22. Pinto C et al: Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): preliminary results (abstract). J Clin Oncol 24(18S;Suppl.v.20. Juni):LBA4031 (Abstract online: http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730adlRCRD&vmview=abst_detail_view&confID= 40&abstractID=32624, Stand: 4. April 2007), 2006.
23. Cunningham D et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1): 11-20, 2006.
24. Boige V et al: Final results of a randomized trial comparing preoperative 5-fluorouracil (F) / cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. ASCO Annual Meeting 2007, Abstract:4510 J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25(18S): 4510, 2007.
25. Hermans J et al: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomised trials. J Clin Oncol 11(8): 1441-1447, 1993.
26. Earle CC and Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35(7): 1059-1064, 1999.
27. Mari E et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 11(7): 837-843, 2000.
28. Panzini I et al: Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomised trials and a comparison with previous meta-analyses. Tumori 88(1): 21-27, 2002.
29. Cascinu S et al: High risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen (abstract). J Clin Oncol 23(16S;Suppl.v.1.Juni):4023 (Abstract online: http://www.asco.org/ portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 34&abstractID=33419, Stand: 4. April 2007), 2005.
30. Macdonald JS et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10): 725-730, 2001.
31. Sakamoto J et al: Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer. A meta-analysis of centrally randomised clinical trials (abstract). J Clin Oncol 24(18S:Suppl.v.20. Juni):LBA4033 (Abstract online:http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 40&abstractID=30272, Stand: 4. April 2007), 2006.
32. Sasako M et al: Randomised phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients (pts) after curative D2 gastrectomy (ACT-GC-study) (abstract). Gastrointestinal Cancers Symposium Orlando, Florida. Proceedings #8. Online: http://www.asco.org/portal/site/ASCO/menuitem.64cfbd0f85cb37b2eda2be0aee37a01d/? vgnextoid=09f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= vm_search_results_view&selectedConfs=45&SearchFilter= Speaker&SearchTerm=sasako) 2007.
33. Hundahl SA et al: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 88: 921-932, 2000.